Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers

Ki vehet részt

• Pathologically confirmed or radiographically diagnosed non-small cell lung cancer, small cell lung cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, sarcoma, thymoma, or left-sided breast cancer
• Planning to receive neo-adjuvant, adjuvant, or definitive radiation therapy to the thorax with curative intent
• Willing to participate in home-based cardiac rehabilitation program and be monitored remotely via smart phone application
• Possess a smart phone or tablet capable of supporting teleHeart application
• Willing and eligible to co-enroll in the Cardiovascular Toxicity in Cancer and Improvement in Recovery (SURVIVE) Registry Study (HRPO# 201801031)
• At least 18 years of age
• ECOG performance status ≤ 2
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)

Ki nem vehet részt

• Presence of distant metastatic disease (except patients with lymphoma)
• Presence of significant cancer disease burden that would make patient unlikely to tolerate cardiac rehabilitation (CR)
• Diagnosis of primary cervical esophageal cancer
• Presence of unstable angina
• Recipient of heart transplant
• Patient on cardiac transplant list or has a ventricular assist device
• Life expectancy less than 6 months
• Patient lives in skilled nursing facility, chronic care facility, nursing home, or palliative care or hospice facility
• Unable to walk
• Patient's baseline weight > 300 lbs (due to weight limitations of the scale and bioelectrical impedance device)
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry
• Other medical comorbidities that make the patient unable to participate in the CR program or other assessments involved with this study